Eliquis 市场：依适应症、疗效、年龄层、剂型、通路和地区划分

Eliquis 市场规模预计在 2025 年达到 79 亿美元，预计在 2032 年达到 113 亿美元，2025 年至 2032 年的复合年增长率为 5.2%。

全球 Eliquis 市场是製药业的关键领域，专注于世界上使用最广泛的抗凝血剂之一。 Eliquis（Apixaban）由百时美施贵宝和辉瑞开发，是一种直接口服抗凝血剂 (DOAC)，属于 Xa 因子抑制剂类。这种突破性的治疗方法改变了各种血栓性栓塞症的治疗前景，包括心房颤动、深层静脉栓塞症和肺动脉栓塞。该市场包括 Eliquis 在多个治疗应用和地区的生产、分销和商业化。随着全球医疗保健系统优先改善患者预后并寻求Warfarin等传统抗凝血剂的替代品，Eliquis 因其卓越的疗效、降低的出血风险和无需常规监测而成为首选。市场发展的特点是医疗保健专业人员的采用率不断提高、适应症不断扩大以及患者对先进抗凝血治疗的认识不断提高。

市场动态

全球 Eliquis 市场受多种因素驱动，推动其在国际医疗保健市场的扩张。全球心房颤动、静脉血栓栓塞症和其他心血管疾病的盛行率不断上升，尤其是人口老化和生活方式相关风险因素加剧了这一趋势，这是一个根本驱动因素。与Warfarin等传统抗凝血剂相比，医疗保健提供者越来越青睐 Eliquis，因为 Eliquis 具有出色的安全性、可预测的药物动力学，并且无需常规监测，从而显着提高了患者的依从性和生活品质。大量临床试验数据证明，Eliquis 在降低中风风险和全身性栓塞方面有效，这已在循环系统和基层医疗医生中得到广泛采用。然而，市场面临重大限制，包括 Eliquis 与非专利抗凝血剂相比价格较高，限制了其在价格敏感市场和预算受限的医疗保健系统中的可用性。专利到期担忧和潜在的学名药竞争对市场独占性构成长期威胁，而某些患者群体中的不利事件和禁忌症则限制了其普遍应用。儘管存在这些挑战，但随着治疗适应症的扩大、新兴市场对深度抗凝血治疗认识的提高以及新兴经济体医疗支出的增加，重大机会正在涌现。精准医疗方法和个人化抗凝血治疗的日益普及为公司提供了进一步的增长途径，而战略伙伴关係关係和在服务欠缺地区的市场扩张倡议，则为不断发展的抗凝血领域中的相关人员带来了巨大的收益潜力。

本次调查的主要特点

• 本报告对全球 Eliquis 市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机，并说明了针对该市场的引人注目的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数概述了全球 Eliquis 市场的主要企业。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球 Eliquis 市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 透过用于分析全球 Eliquis 市场的各种策略矩阵，相关人员可以轻鬆做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章：市场动态、法规与趋势分析

• 市场动态
• 驱动程式
• 抑制因素
• 机会
• 影响分析
• 主要进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 产业趋势
• 流行病学
• 美国的合规率
• 美国开关分析
• 专利到期情景

4. 2020 年至 2032 年全球 Eliquis 市场（依适应症划分）

• 降低非瓣膜性心房颤动患者中风和全身性栓塞的风险
• 髋关节或膝关节关节重建术后深层静脉栓塞症的预防
• 深层静脉栓塞症
• 肺动脉栓塞
• 降低復发性深层静脉栓塞症和肺动脉栓塞的风险
• 降低儿科患者静脉血栓栓塞症(VTE) 和復发性 VTE 的风险

5. 2020 年至 2032 年全球 Eliquis 市场（按效力）

• 2.5mg
• 5mg

6. 2020 年至 2032 年按年龄分類的全球 Eliquis 市场

• 孩子们
• 成人

7. 2020 年至 2032 年全球 Eliquis 市场（以剂型划分）

• 口服锭剂
• 口服悬浮液

8. 2020 年至 2032 年按分销管道分類的全球 Eliquis 市场

• 医院药房
• 零售药局
• 网路药局

9. 2020 年至 2032 年按地区分類的全球 Eliquis 市场

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第十章 竞争格局

• Pfizer Inc.
• Bristol-Myers Squibb Company

第 11 章分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十二章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Eliquis Market is estimated to be valued at USD 7.90 Bn in 2025 and is expected to reach USD 11.30 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032.

The global Eliquis market represents a critical segment within the pharmaceutical industry, focusing on one of the most widely prescribed anticoagulant medications worldwide. Eliquis (apixaban), developed by Bristol Myers Squibb and Pfizer, is a direct oral anticoagulant (DOAC) that belongs to the factor Xa inhibitor class of medications. This revolutionary drug has transformed the treatment landscape for various thromboembolic conditions, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The market encompasses the production, distribution, and commercialization of Eliquis across multiple therapeutic applications and geographical regions. As healthcare systems globally prioritize improved patient outcomes and seek alternatives to traditional anticoagulants like warfarin, Eliquis has emerged as a preferred choice due to its superior efficacy profile, reduced bleeding risks, and elimination of routine monitoring requirements. The market's evolution is characterized by increasing adoption rates among healthcare providers, expanding indications for use, and growing patient awareness about advanced anticoagulation therapies.

Market Dynamics

The global Eliquis market is primarily driven by several compelling factors that collectively fuel its expansion across international healthcare markets. The increasing prevalence of atrial fibrillation, venous thromboembolism, and other cardiovascular conditions worldwide serves as a fundamental growth driver, particularly amplified by aging demographics and lifestyle-related risk factors. Healthcare providers' growing preference for Eliquis over traditional anticoagulants like warfarin stems from its superior safety profile, predictable pharmacokinetics, and elimination of routine monitoring requirements, significantly improving patient compliance and quality of life. The drug's proven efficacy in reducing stroke risk and systemic embolism, supported by extensive clinical trial data, continues to drive adoption among cardiologists and primary care physicians. However, the market faces notable restraints including the high cost of Eliquis compared to generic anticoagulants, which creates accessibility challenges in price-sensitive markets and healthcare systems with budget constraints. Patent expiration concerns and potential generic competition pose long-term threats to market exclusivity, while adverse events and contraindications in certain patient populations limit universal applicability. Despite these challenges, significant opportunities emerge from expanding therapeutic indications, growing awareness about advanced anticoagulation therapies in emerging markets, and increasing healthcare expenditure in developing economies. The rising adoption of precision medicine approaches and personalized anticoagulation therapy presents additional growth avenues, while strategic partnerships and market expansion initiatives in underserved geographical regions offer substantial revenue potential for stakeholders in the evolving anticoagulant therapeutic landscape.

Key Features of the Study

• This report provides in-depth analysis of the global Eliquis market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Eliquis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol Myers Squibb, Pfizer Inc., and other major pharmaceutical distributors and generic manufacturers
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Eliquis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Eliquis market

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation
  • Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
  • Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
• Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • 5 mg
  • 5 mg
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adult
• Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral Tablet
  • Oral Suspension
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Eliquis Market, By Indication
  • Global Eliquis Market, By Strength
  • Global Eliquis Market, By Age Group
  • Global Eliquis Market, By Dosage Form
  • Global Eliquis Market, By Distribution Channel
  • Global Eliquis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends
• Epidemiology
• Adherence rate in U.S.
• Switch analysis in U.S.
• Patent Expiry Scenario

4. Global Eliquis Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Deep Vein Thrombosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pulmonary Embolism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Eliquis Market, By Strength, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 5 mg
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• 5 mg
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Eliquis Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Eliquis Market, By Dosage Form, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral Tablet
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral Suspension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Eliquis Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Eliquis Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Strength, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Dosage Form, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us